PHARMGEN SCIENCE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 5,200 KRW | -0.57% |
|
0.00% | -16.13% |
| 2023 | PharmGen Science, Inc.(KOSE:A004720) dropped from S&P Global BMI Index | CI |
| 2023 | PharmGen Science, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 | CI |
| Sales 2022 | 151B 110M | Sales 2023 | 167B 121M | Capitalization | 111B 80.84M |
|---|---|---|---|---|---|
| Net income 2022 | 70.06B 50.86M | Net income 2023 | 5.73B 4.16M | EV / Sales 2022 | 0.83 x |
| Net Debt 2022 | 19.61B 14.23M | Net Debt 2023 | 526M 382K | EV / Sales 2023 | 0.67 x |
| P/E ratio 2022 |
1.98
x | P/E ratio 2023 |
20.3
x | Employees | 250 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 86.72% |
More Fundamentals
* Assessed data
More news
| 1 day | -0.57% | ||
| Current month | -7.80% | ||
| 1 month | -12.31% | ||
| 3 months | -11.41% | ||
| 6 months | -12.90% | ||
| Current year | -16.13% |
1 week
5 110.00
5 310.00
1 month
5 070.005 990.00
Current year
5 070.006 430.00
1 year
5 070.007 440.00
3 years
5 070.0018 600.00
5 years
4 290.0033 650.00
10 years
2 580.0033 650.00
| Managers | Title | Age | Since |
|---|---|---|---|
Hee-Deok Park
CEO | Chief Executive Officer | 56 | 19-03-26 |
Hye-Yeon Kim
CEO | Chief Executive Officer | 67 | - |
Nam-Hyun Ryu
BRD | Director/Board Member | 58 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Seung-Yeol Lee
BRD | Director/Board Member | 44 | - |
Hye-Yeon Kim
CEO | Chief Executive Officer | 67 | - |
Nam-Hyun Ryu
BRD | Director/Board Member | 58 | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 5,200 | -0.57% | 31,071 |
| 24-04-24 | 5,230 | +0.38% | 48,323 |
| 24-04-23 | 5,210 | +0.58% | 47,328 |
| 24-04-22 | 5,180 | +1.17% | 94,294 |
| 24-04-19 | 5,120 | -1.54% | 164,252 |
End-of-day quote Korea S.E., April 24, 2024
More quotes
PharmGen Science Inc, formerly Wooridul Pharmaceutical Ltd, is a Korea-based company principally engaged in the manufacturing and distribution of pharmaceuticals. The Companyâs products include antiepileptic agents, anti-inflammatory agents, antiphlogistic agents, central nervous system agents, urinary agents, antihistamine agents, antivirus agents, agents for bones, agents for livers, calcium agents, antibiotics, diabetes agents, respiratory agents, as well as over-the-counter (OTC) drugs, obesity drugs, health food and others. In addition, the Company is also engaged in the manufacturing, wholesale and retail distribution of functional cosmetics. The Company distributes its products within domestic market and to overseas markets.
Sector
Pharmaceuticals
Calendar
2024-05-12
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -16.13% | 68.67M | |
| +20.72% | 21.89B | |
| +13.49% | 14.45B | |
| +13.13% | 13.63B | |
| +37.85% | 11.49B | |
| -8.64% | 6.85B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.35% | 5.06B | |
| -5.36% | 4.66B |
- Stock Market
- Equities
- A004720 Stock
